By Denny Jacob
Emergent Biosolutions shares climbed 16% after disclosing that it has secured about $400 million for this year and next for its portfolio of smallpox and monkeypox vaccine products.
Shares were trading around $7.08. The stock is up 55% on the year.
The company, which develops and manufactures medical countermeasures, said its secured orders include a previously disclosed U.S. government contract for smallpox and monkeypox vaccines, among other procurements. Customer orders of nearly $210 million have been delivered to date in 2024, it said.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
September 25, 2024 08:04 ET (12:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。